Eisai Unveils Oncology Portfolio and Pipeline at ASCO 2024

Eisai has announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), held both virtually and in-person in Chicago, Illinois from May 31 to June 4. They are presenting research from their oncology portfolio and pipeline, covering various cancer types.

One notable presentation is on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), examining lenvatinib (LENVIMA®) plus pembrolizumab (KEYTRUDA®) versus sunitinib as a first-line treatment for advanced renal cell carcinoma (Abstract #4504). Additionally, findings on disease progression patterns and subsequent therapy from this trial will be shared in a poster presentation (Abstract #4524).

Dr. Takashi Owa, Chief Scientific Officer and Senior Vice President at Eisai Co., Ltd., emphasized their commitment to patient-centric approaches and scientific advancement in oncology. The research presented aims to shed light on the efficacy of lenvatinib plus pembrolizumab in advanced renal cell carcinoma and explore various modalities in their pipeline to address advanced diseases and improve patient outcomes.

Key research from Eisai’s pipeline includes Phase 3 data from the JBCRG-M06/EMERALD study in Japan, evaluating trastuzumab and pertuzumab in combination with Eisai’s eribulin mesylate or a taxane in patients with HER2-positive breast cancer (NCT03264547; Abstract #1007). Other pipeline research presented in poster sessions covers a Phase 2 study of BB-1701, an antibody drug conjugate targeting HER2, in previously treated patients with HER2-positive or HER2-low breast cancer (NCT06188559; Abstract #TPS1122), among others.

It’s important to note that this release discusses investigational compounds and uses for FDA-approved products, without conveying conclusions about efficacy and safety. The full list of Eisai presentations will be available via the ASCO website on May 23, 2024.

Furthermore, Eisai is collaborating with Merck & Co., Inc., and Bliss Biopharmaceutical (Hangzhou) Co., Ltd., on various projects, including the co-development and co-commercialization of lenvatinib and the investigation of BB-1701 for breast cancer and HER2-expressing solid tumors.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter